Comparative Pharmacology
Head-to-head clinical analysis: MPI DMSA KIDNEY REAGENT versus QUADRAMET.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MPI DMSA KIDNEY REAGENT versus QUADRAMET.
MPI DMSA KIDNEY REAGENT vs QUADRAMET
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DMSA (dimercaptosuccinic acid) labeled with technetium-99m binds to renal cortex, particularly proximal tubular cells, allowing scintigraphic imaging of functional renal parenchyma. Uptake correlates with renal blood flow and tubular function.
Samarium Sm 153 lexidronam is a radiolabeled agent that localizes to areas of osteoblastic bone activity. The samarium-153 isotope emits beta particles and gamma photons, delivering radiation to the bone and surrounding tissues. This results in the destruction of malignant cells in bone metastases.
Adults: 74-185 MBq (2-5 mCi) intravenously, single dose for renal imaging.
1.0 mCi/kg (37 MBq/kg) intravenously as a single dose.
None Documented
None Documented
Initial whole-body half-life of dimer captosuccinic acid (DMSA) is 1.1 hours; terminal elimination half-life for cortical retention is 56 days, reflecting prolonged renal tubular uptake.
Terminal half-life: 6–8 hours (prolonged in renal impairment; may exceed 20 hours in CrCl <30 mL/min).
Renal: ~50% excreted unchanged in urine within 24 hours; remaining fraction retained in renal tubular cells with gradual release over weeks.
Renal: 65% as unchanged drug; biliary/fecal: 20% as metabolites; remainder as other minor metabolites.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical